Android app Apple app link

This Obesity Drug Just Crushed Expectations -- And Sent One Biotech Stock Soaring 14.5%

By Yahoo! Finance   |   3 weeks ago
This Obesity Drug Just Crushed Expectations -- And Sent One Biotech Stock Soaring 14.5%

Rhythm Pharmaceuticals saw a 14.5% surge after its obesity drug, setmelanotide, succeeded in a Phase 3 trial for treating rare conditions. Analysts predict a potential 2035% rally and price target upgrades.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

To become a member, please download and purchase membership through our app.